Innoviva (INVA) closed at $19.10 on November 6, 2026, down 0.7% from the previous close, on volume of 1,375,890 shares (30-day average 732,821).
Data as of November 6, 2026.
Innoviva GAAP EPS of -$1.03 misses by $1.37, revenue of $106.12M misses by $9.19M
Seeking Alpha News (Wed, 4-Nov 5:13 PM ET)
Innoviva Reports Third Quarter 2026 Financial Results; Highlights Recent Company Progress
Business Wire (Wed, 4-Nov 4:05 PM ET)
Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026
Business Wire (Mon, 19-Oct 8:00 AM ET)
Innoviva to Participate in Upcoming Investor Conferences
Business Wire (Wed, 2-Sep 8:00 AM ET)
Business Wire (Tue, 11-Aug 4:05 PM ET)
Innoviva’s Zoliflodacin Phase 3 Results Signal a Turning Point in Gonorrhea Treatment
Market Chameleon (Fri, 12-Dec 2:31 AM ET)
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
Innoviva trades on the NASDAQ stock market under the symbol INVA.
As of November 6, 2026, INVA stock price declined to $19.10 with 1,375,890 million shares trading.
INVA has a beta of -0.14, meaning it tends to be less sensitive to market movements. INVA has a correlation of 0.00 to the broad based SPY ETF.
INVA has a market cap of $1.36 billion. This is considered a Small Cap stock.
Last quarter Innoviva reported $106 million in Revenue and -$1.03 earnings per share. This fell short of revenue expectation by $-9 million and missed earnings estimates by -$1.40.
In the last 3 years, INVA traded as high as $25.15 and as low as $13.31.
The top ETF exchange traded funds that INVA belongs to (by Net Assets): IJR, VTI, IWM, VB, DFSV.
INVA has underperformed the market in the last year with a price return of +4.8% while the SPY ETF gained +9.6%. INVA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -6.9% and -9.3%, respectively, while the SPY returned -4.2% and -3.8%, respectively.
INVA support price is $18.91 and resistance is $19.57 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INVA shares will trade within this expected range on the day.